Abstract:
To evaluate the anticancerous effects of different dilutions of metformin were evaluated for in vitro anticancerous effects, primarily breast cancer cells (MCF-7, MDA-MB-231). This prospective experimental study was
conducted in Department of Pharmacology & Therapeutics BMSI in alliance with PCMD. The duration of study was
from March 2016 to February 2017. For evaluating the anticancerous effects of different dilutions of Metformin (0.5µM
-100µM) we used 4 different cancerous cells lines; MCF-7, HT-29, MDA-MB-231 and Hela. For assessment of
anticancerous effects we used MTT assay by which assessed IC50, SI, % viability of all cells and Trypan blue exclusion
assay for only MCF-7 cell line. The % viability of MCF-7 was significantly decreases (χ2
(2) = 26.48, p=<0.001) in dose
dependent manner from 99.8±0.2 to 39.71±1.3. For MDA-MB-231% viability significantly reduced (χ2
(2) =26.48,
p=<0.001) from 99.474± 0.298 to 51.55±4. However Metformin had statistically no significant dose dependent effects
on % viability of MCF-10 (χ2 (2) = 11.709, p=0.069). Metformin significantly exhibited the anticancerous effects on
breast cancerous cells by selectively target the cancerous cells without any effects on normal epithelial cells of breast.
